GlycoMimetics to Report Fourth Quarter and Year-End 2018 Financial Results on March 6, 2019
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its fourth quarter
and fiscal year 2018 financial results on Wednesday, March 6, 2018, at 8:30 a.m. ET.
The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international
participants, with participant code 5072004. A webcast replay will be available via the “Investors” tab on
the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the
close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants,
participant code 5072004.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial
as a potential treatment for AML and is currently being evaluated in a company-sponsored Phase 3 trial in relapsed/refractory
AML. The U.S. Food and Drug Administration granted uproleselan breakthrough therapy designation for the treatment of
adult AML patients with relapsed/refractory disease. GlycoMimetics has also completed a Phase 1 clinical trial with a third
drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the clinical development of the company’s drug candidates,
including the expected enrollment in and conduct of clinical trials, the presentation of clinical data, and expiration of issued
patents. Actual results may differ materially from those in these forward-looking statements. For a further description of the
risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the
company’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 6, 2018, and other
filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release,
and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.
Source: GlycoMimetics, Inc.
Investor Contact:
Shari Annes
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media Contact:
Jamie Lacey-Moreira
Phone: 410-299-3310
Email: jamielacey@presscommpr.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190227005903/en/